• Je něco špatně v tomto záznamu ?

Pharmacological Foundations of Cannabis Chemovars

MA. Lewis, EB. Russo, KM. Smith,

. 2018 ; 84 (4) : 225-233. [pub] 20171121

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18033539

An advanced Mendelian Cannabis breeding program has been developed utilizing chemical markers to maximize the yield of phytocannabinoids and terpenoids with the aim to improve therapeutic efficacy and safety. Cannabis is often divided into several categories based on cannabinoid content. Type I, Δ9-tetrahydrocannabinol-predominant, is the prevalent offering in both medical and recreational marketplaces. In recent years, the therapeutic benefits of cannabidiol have been better recognized, leading to the promotion of additional chemovars: Type II, Cannabis that contains both Δ9-tetrahydrocannabinol and cannabidiol, and cannabidiol-predominant Type III Cannabis. While high-Δ9-tetrahydrocannabinol and high-myrcene chemovars dominate markets, these may not be optimal for patients who require distinct chemical profiles to achieve symptomatic relief. Type II Cannabis chemovars that display cannabidiol- and terpenoid-rich profiles have the potential to improve both efficacy and minimize adverse events associated with Δ9-tetrahydrocannabinol exposure. Cannabis samples were analyzed for cannabinoid and terpenoid content, and analytical results are presented via PhytoFacts, a patent-pending method of graphically displaying phytocannabinoid and terpenoid content, as well as scent, taste, and subjective therapeutic effect data. Examples from the breeding program are highlighted and include Type I, II, and III Cannabis chemovars, those highly potent in terpenoids in general, or single components, for example, limonene, pinene, terpinolene, and linalool. Additionally, it is demonstrated how Type I - III chemovars have been developed with conserved terpenoid proportions. Specific chemovars may produce enhanced analgesia, anti-inflammatory, anticonvulsant, antidepressant, and anti-anxiety effects, while simultaneously reducing sequelae of Δ9-tetrahydrocannabinol such as panic, toxic psychosis, and short-term memory impairment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033539
003      
CZ-PrNML
005      
20181015114056.0
007      
ta
008      
181008s2018 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1055/s-0043-122240 $2 doi
035    __
$a (PubMed)29161743
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Lewis, Mark A $u Napro Research, Westlake Village, CA, USA.
245    10
$a Pharmacological Foundations of Cannabis Chemovars / $c MA. Lewis, EB. Russo, KM. Smith,
520    9_
$a An advanced Mendelian Cannabis breeding program has been developed utilizing chemical markers to maximize the yield of phytocannabinoids and terpenoids with the aim to improve therapeutic efficacy and safety. Cannabis is often divided into several categories based on cannabinoid content. Type I, Δ9-tetrahydrocannabinol-predominant, is the prevalent offering in both medical and recreational marketplaces. In recent years, the therapeutic benefits of cannabidiol have been better recognized, leading to the promotion of additional chemovars: Type II, Cannabis that contains both Δ9-tetrahydrocannabinol and cannabidiol, and cannabidiol-predominant Type III Cannabis. While high-Δ9-tetrahydrocannabinol and high-myrcene chemovars dominate markets, these may not be optimal for patients who require distinct chemical profiles to achieve symptomatic relief. Type II Cannabis chemovars that display cannabidiol- and terpenoid-rich profiles have the potential to improve both efficacy and minimize adverse events associated with Δ9-tetrahydrocannabinol exposure. Cannabis samples were analyzed for cannabinoid and terpenoid content, and analytical results are presented via PhytoFacts, a patent-pending method of graphically displaying phytocannabinoid and terpenoid content, as well as scent, taste, and subjective therapeutic effect data. Examples from the breeding program are highlighted and include Type I, II, and III Cannabis chemovars, those highly potent in terpenoids in general, or single components, for example, limonene, pinene, terpinolene, and linalool. Additionally, it is demonstrated how Type I - III chemovars have been developed with conserved terpenoid proportions. Specific chemovars may produce enhanced analgesia, anti-inflammatory, anticonvulsant, antidepressant, and anti-anxiety effects, while simultaneously reducing sequelae of Δ9-tetrahydrocannabinol such as panic, toxic psychosis, and short-term memory impairment.
650    _2
$a biologické markery $x metabolismus $7 D015415
650    _2
$a kanabidiol $x metabolismus $7 D002185
650    _2
$a kanabinoidy $x biosyntéza $x farmakologie $7 D002186
650    _2
$a Cannabis $x genetika $x metabolismus $7 D002188
650    _2
$a tetrahydrokanabinol $x analogy a deriváty $x metabolismus $7 D013759
650    _2
$a šlechtění rostlin $7 D000069600
655    _2
$a časopisecké články $7 D016428
700    1_
$a Russo, Ethan B $u International Cannabis and Cannabinoids Institute, Prague, Czech Republic.
700    1_
$a Smith, Kevin M $u Napro Research, Westlake Village, CA, USA.
773    0_
$w MED00003839 $t Planta medica $x 1439-0221 $g Roč. 84, č. 4 (2018), s. 225-233
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29161743 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181015114553 $b ABA008
999    __
$a ok $b bmc $g 1340196 $s 1030533
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 84 $c 4 $d 225-233 $e 20171121 $i 1439-0221 $m Planta medica $n Planta Med $x MED00003839
LZP    __
$a Pubmed-20181008

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...